pVHL mediates K63-linked ubiquitination of nCLU

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Xue, Jing ^a   Lv, Dan dan ^a   Jiao, Shi ^a   Zhao, Wenting ^a   Li, Xuebing ^a   Sun, Heng ^a   Yan, Bing ^a   Fan, Li ^a   Hu, Rong gui ^b   Fang, Jing ^a  

^a Chinese Academy of Sciences   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CLUSTERIN; NUCLEAR CLUSTERIN; PRODUCT OF VON HIPPEL LINDAU PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN;

ARTICLE; BINDING KINETICS; HUMAN; HUMAN CELL; K63 LINKED UBIQUITINATION; NUCLEAR TRANSLOCATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; REGULATORY MECHANISM; UBIQUITINATION; CELL NUCLEUS; CELL STRAIN HEK293; GENETICS; METABOLISM; PHYSIOLOGY;

CELL NUCLEUS; CLUSTERIN; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84859994526     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035848     Document Type: Article

References (33)

1. Frew IJ, Krek W, (2008) pVHL: a multipurpose adaptor protein. Sci Signal 1: e30.
2. Kim WY, Kaelin WG, (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004.
3. Kaelin WG, (2007) Von Hippel-Lindau disease. Annu Rev Pathol 2: 145-173.
4. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, et al. (1999) Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284 (5414): 657-61.
5. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, et al. (1999) Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96: 12436-12441.
6. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W, (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13: 1822-1833.
7. Schofield CJ, Ratcliffe PJ, (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354.
8. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
9. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
10. Kaelin WG Jr, (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
11. Czyzyk-Krzeska MF, Meller J, (2004) von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends Mol Med 10: 146-149.
12. Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, et al. (2001) The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 276: 43611-43617.
13. Grosfeld A, Stolze IP, Cockman ME, Pugh CW, Edelmann M, Kessler B, Bullock AN, Ratcliffe PJ, Masson N, (2007) Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor. J Biol Chem 282: 13264-13269.
14. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, et al. (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1: 959-968.
15. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, et al. (2007) pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28: 15-27.
16. Chitalia VC, Foy RL, Bachschmid MM, Zeng LL, Panchenko MV, et al. (2008) Jade-1 inhibits Wnt signaling by ubiquitilating β-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 10: 1208-1216.
17. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG, (2004) Modulation of different clusterin isoforms in human colon tumorigenesis, Oncogene 23: 2298-2304.
18. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, et al. (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death and Diff 13: 12-19.
19. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA, (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 274: 11590-11600.
20. de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J, (1990) A Apolipoprotein J: structure and tissue distribution. Biochemistry 29: 5380-5389.
21. Klock G, Baiersdörfer M, Koch-Brandt C, (2009) Chapter 7: Cell protective functions of secretory Clusterin (sCLU). Adv Cancer Res 104: 115-138.
22. Bettuzzi S, Rizzi F, (2009) Chapter 5: Nuclear CLU (nCLU) and the fate of the cell. Adv Cancer Res 104: 59-88.
23. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, et al. (2006) Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein. Am J Pathol 168: 574-584.
24. Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J, (2010) Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 138: 606-615.
25. Kuznetsova AV, Meller J, Schnell PO, Nash JA, Ignacak ML, et al. (2003) von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 100: 2706-2711.
26. Rizzi F, Caccamo AE, Belloni L, Bettuzzi S, (2009) Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol 219: 314-323.
27. Yang W-L, Zhang X, Lin H-K, (2010) Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene 29: 4493-4503.
28. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD, (2006) Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation. Nature Cell Biol 8: 398-406.
29. Pickart CM, (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 503-533.
30. van Wijk SJ, de Vries SJ, Kemmeren P, Huang A, Boelens R, et al. (2009) A comprehensive framework of E2-RING E3 interactions of the human ubiquitin-proteasome system. Mol Syst Biol 5: 295.
31. Nath D, Shadan S, (2009) The ubiquitin system. Nature 458: 421.
32. Bhoj VG, Chen ZJ, (2009) Ubiquitylation in innate and adaptive immunity. Nature 458: 430-437.
33. Geetha T, Kenchappa RS, Wooten MW, Carter BD, (2005) TRAF6-mediated ubiquitination regulates nuclear translocation of NRIF, the p75 receptor interactor. EMBO J 24: 3859-3868.